HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
申请人:CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.
公开号:US20170253614A1
公开(公告)日:2017-09-07
A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.
Development of Effective Bidentate Diphosphine Ligands of Ruthenium Catalysts toward Practical Hydrogenation of Carboxylic Acids
作者:Shota Yoshioka、Ke Wen、Susumu Saito
DOI:10.1246/bcsj.20210023
日期:2021.5.15
represents one of the most ideal reduction methods for utilizing abundant CAs as alternative carbon and energy sources. However, systematic studies on the effects of metal-to-ligand relationships on the catalytic activity of metal complex catalysts are scarce. We previously demonstrated a rational methodology for CA hydrogenation, in which CA-derived cationic metal carboxylate [(PP)M(OCOR)]+ (M = Ru and Re;
将羧酸(CA)加氢成醇代表了最理想的还原方法之一,该方法可利用丰富的CA作为替代碳和能源。但是,关于金属与配体之间的关系对金属络合物催化剂催化活性的影响的系统研究很少。我们之前展示了一种合理的CA加氢方法,其中CA衍生的阳离子金属羧酸盐[(PP)M(OCOR)] +(M = Ru和Re; P =一个P配位)用作CA自诱导的CA氢化的催化剂原型。本文中,我们报告了有关如何通过修饰分子Ru催化剂的双齿二膦(PP)配体结构来实现更高催化活性的系统试验研究。连接两个P原子以及PP配体的P原子上取代的Ar基的碳链发生剧烈变化,并且从预催化剂Ru(acac)3诱导了活性Ru催化剂被广泛调查。结果,(PP)Ru催化剂的活性和耐用性与其他分子式Ru催化剂体系(包括我们的原始Ru催化剂)相比大大提高了。结果证实了我们改进催化剂性能的方法,这将有利于CA自诱导CA加氢的进一步发展。